Gelsolin amyloidosis is a dominantly inherited, incurable type of amyloidosis. A single point mutation in the gelsolin gene (G654A is most common) results in the loss of a Ca 2þ binding site in the second gelsolin domain. Consequently, this domain partly unfolds and exposes an otherwise buried furin cleavage site at the surface. During secretion of mutant plasma gelsolin consecutive cleavage by furin and MT1-MMP results in the production of 8 and 5 kDa amyloidogenic peptides. Nanobodies that are able to (partly) inhibit furin or MT1-MMP proteolysis have previously been reported. In this study, the nanobodies have been combined into a single bispecific format able to simultaneously shield mutant plasma gelsolin from intracellular furin and extracellular MT1-MMP activity. We report the successful in vivo expression of this bispecific nanobody following adeno-associated virus serotype 9 gene therapy in gelsolin amyloidosis mice. Using SPECT/CT and immunohistochemistry, a reduction in gelsolin amyloid burden was detected which translated into improved muscle contractile properties. We conclude that a nanobody-based gene therapy using adeno-associated viruses shows great potential as a novel strategy in gelsolin amyloidosis and potentially other amyloid diseases.
Introduction
Gelsolin amyloidosis (AGel) is an autosomal dominantly inherited disease caused by a point mutation in the gelsolin (GSN) gene (G654A being the most common, D187N) (1, 2) . The resulting destabilization of the second gelsolin domain (gelsolin consist of 6 domains, G1-G6) results in an aberrant proteolytic cascade, specifically affecting the plasma variant (3) (4) (5) (6) . During its transport through the intracellular secretion pathway, mutant plasma gelsolin (PG*), is first cleaved by furin in the transGolgi network leading to the formation of a 68 kDa C-terminal fragment (7) . When this C68 fragment is secreted, a second proteolytic cleavage by MT1-MMP like proteases results in the release of 8 and 5 kDa amyloidogenic fragments (8) . Over time, particularly the 8 kDa peptide will start to aggregate, forming cross-beta-sheet amyloid fibrils and plaques. Patients experience a triad of neurological, ophthalmological and dermatological symptoms (9, 10) . At the moment, no specific treatments for AGel are available. Instead, patients undergo several symptomatic and aesthetic treatments to improve their quality of life.
Our previous studies have shown that chaperoning nanobodies are able to (partly) inhibit the pathological furin and MT1-MMP cleavages in vitro and in vivo, resulting in physiological improvements in transgenic mice that recapitulate the proteolytic AGel cascade (11, 12) . In view of the central roles that furin and MT1-MMP undertake in neuropeptide maturation and connective tissue organization/activation of other metalloproteases, respectively, we argue that these proteases should not be considered as therapeutic targets, particularly since familial amyloidosis is a chronic disease. For this reason we used camelid nanobodies that interact specifically with (mutant) gelsolin and shield the protein either from furin (12) or MT1-MMP degradation (11) , thus acting as molecular chaperones.
In the present study, we combined the two nanobodies into a single bispecific format with the aim of providing simultaneous protection against both proteases simultaneously. The nanobodies were separated by an MT1-MMP-sensitive peptide sequence which was used as an MT1-MMP protease decoy. We investigated if this approach affected the binding characteristics of the individual nanobodies and if this format was able to significantly increase the chaperoning capacity in vitro.
Because furin is an intracellular protease, our approach required intracellular delivery of the protective bispecific nanobody. We opted for adeno-associated virus serotype 9 (AAV9) gene therapy (13) considering that AAVs are able to infect both dividing and quiescent cells. Moreover, they remain episomally present in the host cell nucleus, thereby preventing the possibility of insertional mutagenesis.
Using a recently developed nanobody based imaging agent (14) and immunohistochemistry, we provide evidence of a significant decrease in gelsolin amyloid buildup in both the skeletal muscle and heart of AGel mice injected with AAV9-Nb11-FAF1 vector during the neonatal period. These results are further supported by improved muscle contractile properties following treatment.
Results

Production of the bispecific nanobody
In a previous study, we have identified a gelsolin nanobody, Nb11, capable of partly inhibiting the production of C68 by furin (12) . Nb11 binds (mutant) plasma gelsolin irrespective of calcium, and acts as a molecular chaperone when targeted to the trans-Golgi network where it binds to and protects gelsolin. Further downstream, reduced C68 formation results in a decrease of AGel amyloid buildup. In another study, we followed a different approach and identified three closely related nanobodies, FAF Nb1, 2 and 3, (FAF1-3) capable of binding both C68 and the 8 kDa amyloidogenic gelsolin fragment, thwarting MT1-MMP activity, not furin. In vivo, upon binding of C68, these nanobodies once again acted as a chaperone and partly prevented production of the pathological 8 kDa AGel fragment (11) . Here our aim was to combine the two in a clinically applicable way.
Nb11 cDNA was amplified through PCR, introducing a HA-tag at the 5' end and the sequence encoding the MT1-MMP sensitive peptide SLAPLGLQRR (15) , sandwiched between two Gly-Ser linkers (GS) at the 3' end. This fragment was linked to the 5' end of FAF Nb1-3 cDNA, already present in the pHEN6-V5-His 6 vector, resulting in a final construct where both nanobodies occur in tandem configuration, separated by the MT1-MMP sensitive peptide sequence and GS linker (Fig. 1A) .
Bispecific gelsolin nanobodies merge the binding characteristics of their monovalent constituents in vitro
The binding characteristics of the bispecific nanobodies were compared to their monovalent counterparts using ELISA. As antigen, PG, PG*, C68 and the 8 kDa AGel fragment were coated. CapG was chosen as a negative control. This protein belongs to the same family as gelsolin and displays 49% similarity (16) . Nb11 recognized, in decreasing order of magnitude, PG, PG*, C68 and 8 kDa. The FAF Nbs displayed the opposite binding pattern, as previously described (11, 12) . The bispecific Nb11-FAF combinations exhibited a merge of the Nb11 and FAF1-3 binding characteristics ( Fig. 2A and Supplementary Material, Fig. S1 ). No significant binding with the negative control was observed. Furthermore, as previously described (11), FAF Nb1-3 can be used in Western blotting as primary antibodies against PG, PG*, C68 and the 8 kDa AGel fragment. Linked to Nb11, this ability remained unaffected ( Fig. 2B and C) . and C-terminal V5-His6 tag is present (A). The expression cassette was cloned in a self-complementary (sc) adeno-associated virus backbone that was packaged using AAV serotype 9 capsids (AAV9). Expression of Nb11-FAF1 is driven by the CMV promoter. The 5' and 3' inverted terminal repeats (ITR) and SV40 polyadenylation site (pA) are indicated (B).
The MT1-MMP peptide linker is functional in an in vitro setup
As mentioned earlier, the linker between Nb11 and FAF Nb1-3 contains the MT1-MMP sensitive peptide SLAPLGLQRR (proteolysis of the GL scissile bond). The purpose of this setup was that, in vivo, during secretion, proteolysis of this sequence would release the FAF Nb, enabling it to perform its function without any interference of Nb11. At the same time this mechanism may act as a decoy, luring MT1-MMP away from the (lower amount of) C68 being secreted. This was tested in vitro using the recombinant catalytic domain of MT1-MMP. The MT1-MMP sensitive peptide proved to be very efficient in all three bivalent Nb11-FAF constructs and they were readily cleaved upon incubation with MT1-MMP (Fig. 3) . Combined furin/MT1-MMP cleavage assay -bivalent Nb11-FAF Nb protects D187N plasma gelsolin against combined furin-MT1-MMP proteolysis Since Nb11 can inhibit furin proteolysis of PG* whereas FAF1-3 counteract MT1-MMP proteolysis of C68 by shielding the substrate, we hypothesized that bivalent Nb11-FAF formats might be able to combine both traits, leading to a synergetic inhibitory effect on 8 kDa amyloidogenic peptide production. An in vitro assay was set up wherein the nanobodies were incubated with PG*, followed consecutively, by furin and MT1-MMP proteolysis. Formation of both C68 and the 8 kDa fragment was assessed by Western blotting (Fig. 4A) . Only Nb11-FAF1 could match the inhibitory capacity of Nb11 when looking at C68 formation, the intermediate AGel species formed by furin (Fig. 4B) . Quantification of the amyloidogenic 8 kDa fragment showed that all three Nb11-FAF constructs were able to inhibit formation of the 8 kDa AGel peptide more efficiently than their monovalent counterparts (Fig. 4C) . Hence, the bivalent format is endowed with a double protective activity, and the formation of the 8 kDa fragment in particular is strongly reduced in comparison to monospecific Nb11 or FAF nanobodies.
Furin assay in HEK293T -bivalent Nb11-FAF Nb inhibit furin proteolysis
In the in vitro setup Nb11-FAF1-3 were able to bind their antigen targets and showed a significant protective chaperone activity towards PG* and C68. As we wanted to confirm this in a more complex environment, PG, PG* and the Nb11-FAF constructs were transiently expressed in HEK293T cells. Since the first step in AGel pathogenesis, furin cleavage, takes place in the transGolgi network, all constructs were equipped with an N-terminal ER-targeting sequence. Co-staining of the constructs followed by epifluorescence microscopy confirmed their colocalisation along the secretory pathway (Supplementary Material, Figs S2A and S3). After 24 h, we analyzed the cell medium via Western blotting (Supplementary Material, Fig. S2B ). Quantification of the C68 signal revealed a similar pattern as in the in vitro setup; the bispecific Nb11-FAF nanobodies show an inhibitory effect towards furin proteolysis, however none can outperform monovalent Nb11 in this cell based setup (Supplementary Material, Fig. S2C ). We were unable to assess the effect on MT1-MMP proteolysis as no 8 kDa peptide could be detected within the observed timeframe.
Bispecific Nb11-FAF1 gene therapy in AGel mice via AAV9
Since the bispecific nanobodies effectively combined the binding and therapeutic characteristics of its monovalent counterparts, an AGel mouse model intervention study was set up. This mouse model recapitulates the pathological AGel pathway in its muscle tissue, leading to extensive, age related, extracellular amyloidogenic gelsolin buildup (17) . Nb11-FAF1 was chosen based on its superior characteristics in vitro. Homozygote neonates (2-3 days old) were injected with 4.7 x 10 10 vg/mouse of AAV9-Nb11-FAF1, AAV9-Luc2 (viral control) (18, 19) or PBS (negative control) via the retro-orbital plexus. No adverse effects on the development or behavior of the mice were apparent. Nanobody expression was confirmed at 1, 2 and 3 months of age in the plasma of both WT and AGel mice (Fig. 5 ). The presence of a band at 34 kDa and two at 17 kDa indicates that the MT1-MMP sensitive linker is functional in vivo ( Fig. 5 ). At the age of 3 months Nb11-FAF1 gene therapeutic efficacy was determined via SPECT-CT, immunofluorescence and ex vivo muscle performance.
AAV9-Nb11-FAF1 displays therapeutic properties in AGel mice
SPECT-CT imaging. 3 months post treatment, AGel amyloid burden in skeletal muscle and myocardium was determined using SPECT/CT and a recently developed 99m
Tc-FAF Nb1 AGel tracer (14) . In the WT control groups, AAV treatment did not significantly alter the background control signal ( Fig. 6A and B ). In the AGel group however, expression of Nb11-FAF1 resulted in a significantly lower signal (t-test, p< 0.05) in the skeletal muscle (25% vs. PBS and 28% vs. AAV9-ctrl) ( Fig. 6A ) and a significantly lower signal (t-test, p< 0.05) in the heart (30% vs. PBS and 36 vs. AAV9-ctrl) (Fig. 6B ). This is consistent with a reduction of the characteristic amyloid burden in the AAV9-Nb11-FAF1-treated AGel mice.
Immunofluorescence. The mice were sacrificed three months post AAV injection. AGel amyloidogenic buildup in skeletal muscle and heart tissue was stained and quantified. Laminin was used as an internal control. Nb11-FAF1 expression resulted in a significant reduction (t-test, p< 0.05) of AGel amyloidogenic buildup in skeletal muscle (39% vs. PBS and 36% vs. AAV9-ctrl) ( Fig. 7C ) and in the heart (43% vs. PBS and 55% vs AAV9-ctrl) ( Fig. 7D ) in AGel mice. In contrast, WT control groups expressing Nb11-FAF1 showed no significantly different staining compared to the WT-PBS or WT-AAV9-Ctrl groups (Fig. 7A) .
Ex vivo muscle performance is improved in AAV9-Nb11-FAF1 treated mice. At the end of the trial, mice were anaesthetized, the extensor digitorum longus (EDL) and soleus were dissected and their contractile properties were measured. The expression of Nb11-FAF1 in AGel mice resulted in a specific twitch force indistinguishable from the WT control groups (t-test, p< 0.05) and significantly different compared to the untreated (PBS or AAV9-ctrl) AGel groups in EDL muscle (t-test, p< 0.05) but not in the soleus ( Fig. 8A and B) . The amount of force that could be produced for a given frequency (force-frequency) was not affected by the amyloid burden nor by the treatment. Interestingly, fatigue progression was, both in EDL and soleus, significantly more pronounced in the WT versus the (un)treated FAF mice (data not shown). However, the speed of muscle contraction during fatigue in EDL muscle in the Nb11-FAF1 expressing AGel mice showed, as expected, a similar decline as the WT controls in contrast to the untreated (PBS or AAV9-ctrl) AGel mice (Fig.  8D ). The soleus seemed unaffected (Fig. 8C ).
Discussion
As is the case in the majority of amyloid diseases, AGel is characterized by a systemic deposition of amyloid fibrils. The amyloidogenic 8 kDa fragment is produced in a two step process; the first intracellular cleavage of PG* by furin is followed by an extracellular cleavage of C68 by MT1-MMP like proteases. Both in the present and previous studies, intra-and extracellularly active chaperoning nanobodies have been investigated regarding their potential to inhibit the formation of the amyloidogenic 8 kDa gelsolin fragment. The in vivo success of such chaperone based therapeutics strongly depends on the degree in which they distribute throughout the body. In the case of the extracellularly active FAF Nb1, systemic distribution was achieved by intraperitoneal injection (11) . For the intracellularly active Nb11 study, a transgenic mouse model, constitutively expressing Nb11, had to be developed (12) . Here our aim was to combine the FAF Nbs and Nb11 into a single format administered in a clinically applicable way; AAV9 based gene therapy. Three bispecific nanobodies, Nb11-FAF1, Nb11-FAF2 and Nb11-FAF3 (Fig. 1A) , were created. ELISA and Western blot analysis ( Fig. 2 and Supplementary Material, Fig. S1 ) showed that, when linked together, the binding characteristics of the constituent nanobodies remained intact. The peptide used to link the two nanobodies was chosen for its susceptibility towards MT1-MMP proteolysis. We envisaged that this approach would result in proteolysis of the amino acid stretch in vivo upon secretion of C68, thereby releasing the FAF Nbs, after which they can exert their C68 chaperoning capacity in an unhindered manner. In vitro, this peptide sequence performed perfectly; incubation of the bispecific nanobodies with MT1-MMP resulted in the intact release of both constituent nanobodies (Fig. 3) .
The chaperone activities of Nb11-FAF constructs were tested in vitro in a combined furin/MT1-MMP assay. Quantification of C68 and the 8 kDa peptide revealed that Nb11-FAF1 can rival with Nb11's PG* chaperoning activity. At the level of the 8 kDa peptide, all Nb11-FAF constructs outperformed their monovalent counterparts (Fig. 4) .
To address the in vivo problem of amyloid buildup in the AGel mouse model we used a therapeutic approach involving on AAV vector-mediated delivery of the cDNA encoding the Nb11-FAF1 nanobody. AAV is a promising vector for gene therapy yielding long-term episomal expression of therapeutic proteins in clinical trials. The vector tropism is determined by the type of AAV capsid used. We and others had previously demonstrated that AAV serotype 9 is well suited for cardiac and skeletal muscle gene delivery (19) (20) (21) (22) (23) . Moreover, the first systemic AAV9 clinical therapy was initiated in 2014, in children up to nine months old, suffering from spinal muscular atrophy type 1 (24) , resulting in an apparent sustained therapeutic effect. Since the AGel mouse model recapitulates AGel pathology in skeletal muscle and heart, we therefore also opted for AAV9. In vivo transduction with AAV9 vectors encoding the Nb11-FAF1 nanobody resulted in long-term expression of Nb11-FAF1, at least for 3 months post vector-injection, the endpoint of the study (Fig. 5) . This is consistent with previous studies showing prolonged expression in the muscle after AAV gene therapy with many different serotypes, including AAV9 (19) (20) (21) (22) (23) .
Analysis by SPECT/CT and immunohistochemistry revealed a significant decrease in AGel amyloid buildup in both muscle and heart tissue ( Figs 7 and 8) , consistent with Nb11-FAF1 nanobody expression. The pathological AGel amyloid accumulation could be readily detected using anti-8 kDa antiserum or nanobodies in AGel mice, whereas it was absent in wild-type mice. Most importantly, the observed decrease in AGel buildup translated into improved muscle contractile properties. The EDL showed a specific twitch force indistinguishable from the WT control groups but significantly different from the untreated AGel mice. However, the fact that untreated AGel mice show the highest specific twitch force, and that Nb11-FAF1 treatment reduces this back to the WT base level, is quite counterintuitive. One would expect that the presence of AGel amyloid between the muscle fibers would negatively influence overall muscle performance. At the moment the molecular mechanisms behind this observation are still obscure. One possibility would be that in AGel affected muscle tissue, the fraction of unaffected muscle fibers somehow overcompensates the functional loss of the more affected fibers. EDL from Nb11-FAF1 treated mice also displayed improved relaxation speeds at the onset of fatigue (Fig. 8) . The decline in the speed of muscle contraction during fatigue was identical to the one observed in the wild type mice. In contrast, in the untreated AGel control mice, the presence of AGel amyloid around the muscle fibers most likely hinders an efficient exchange of nutrients and metabolites, adversely impacting the relaxation rate. A reduction in AGel deposition, due to Nb11-FAF1 gene therapy, seems to ameliorate this pathological feature. Our results are consistent with our previous studies, showing that intraperitoneal administration of purified monovalent FAF Nbs or transgenic mice expressing Nb11 following insertion in the ROSA26 locus, also resulted in a Tc-FAF Nb1 AGel tracer (14) . Identical regions of interest were drawn around hind leg muscles and heart. Signal quantification showed that Nb expression had no effect on WT background signal, neither in skeletal muscle (A) nor in heart (B). In AGel mice, Nb11-FAF1 expression resulted in a significantly lower signal in skeletal muscle (A) and the heart (B) compared to PBS and AAV9-control groups. Data shown as mean 6 SE. *P < 0.05 in a two sided unpaired t-test. significant reduction of the AGel amyloid burden. Head to head studies in the same AGel mouse model are required to compare the relative efficiencies of this Nb11-FAF1 nanobody-based gene therapy approach versus injections of purified nanobodies. Nevertheless, the main advantage of the current nanobodybased AAV9-dependent gene therapy approach is that it enabled sustained in vivo nanobody expression that is targeted for secretion following passage through the ER and Golgi apparatus where it binds mutant plasma gelsolin. Consequently, the current gene therapy approach is well suited to treat a monogenic disorder like AGel that requires life-long treatment. In contrast, treatment of AGel patients with purified nanobodies, would require life-long, fairly frequent nanobody injections, due to their relatively rapid clearance rates from the circulation. It is particularly encouraging that a long-term therapeutic effect was observed after AAV9-Nb11-FAF1 gene therapy in homozygous AGel mice, which have a more severe phenotype than their heterozygous counterparts (which were used in our earlier studies (11, 12) ). In particular, homozygosity of the D187N mutant PG gene results in an earlier onset and higher degree of AGel amyloid deposition leading to a more significant muscle impairment, as opposed to heterozygous AGel mice (17) .
Despite the advantages of AAV, some challenges would still need to be addressed to enable its widespread use in patients afflicted by monogenic disorders like AGel. First, there is a high prevalence of pre-existing immunity in the human population (40-80%) against the known AAV serotypes (25) . In time this may be overcome by the discovery of new serotypes against which there is almost no pre-existing immunity or by mutating the antigen epitopes on the AAV capsid. Using directed evolution, the latter has already proven to be at least partly successful (26, 27) . Secondly, off-target transduction can severely abate the AAV therapeutic efficiency. Any vector taken up by the off-target tissue is essentially lost as it can no longer exert its effect in the desired target tissue. Consequently, this requires higher viral doses, thereby increasing the risk of an immune response. Moreover, since AAV9 also transduces the liver, any nanobody produced in this organ would no longer be able to perform its PG* chaperone activity. Looking forward to applications in patients, such off-target transductions will have to be minimized. Once again mutagenesis of specific capsid proteins can redirect AAVs more specifically to the tissue of interest (28) (29) (30) . In the case of AGel, and more generally in the case of amyloidosis, this may prove useful as the amyloid precursors are quite often formed in a specific cell type, tissue or organ.
Preventing the formation of amyloid precursors, as was attempted here with nanobodies, would be a major step forward in amyloid research. Currently, administration of (
pyrrolidine-2-carboxylic acid (CPHPC) followed by anti-SAP antibody is the most promising amyloid removing strategy, as has been proven in patients with AL amyloidosis (31) . Obviously, such interventions are only meaningful if, as is the case in AL amyloidosis, one is also able to stop the production of new amyloid precursors. The development of this bispecific, chaperoning, anti-AGel nanobody, may prove to be a fundamental step towards this goal.
Materials and Methods
Antibodies and reagents
Anti-mouse/rabbit IgG HRP conjugate was purchased from VWR (Leuven, Belgium). Polyclonal anti-V5 antibody (1:100 in IHC) was purchased from Sigma-Aldrich (Diegem, Belgium). Alexa fluor 488 goat anti-rat IgG (H þ L) and 594 goat anti-rabbit IgG (H þ L) were purchased from Life Technologies (Merelbeke, Belgium) (both 1:500 in IHC). Monoclonal anti-laminin antibody (1:500 in IHC) was obtained from Abcam (Cambridge, UK). panels, data shown as mean 6 SE. *P < 0.05 in a two sided unpaired t-test). EDL maximum slope (D), during the fatigue protocol, in Nb11-FAF1 expressing AGel mice, displayed the same delay as the WT controls. In contrast, AGel PBS and AAV9-control treated mice displayed a significantly faster fatigue onset. The soleus maximum slope during fatigue protocol (C) seemed unaffected. *P < 0.05 in a two-sided unpaired t-test (A,B), one way ANOVA (C,D).
Generation of gelsolin-specific nanobodies
Both the anti-gelsolin nanobodies (Nb11 and Nb13) and the anti-8 kDa nanobodies (FAF Nb1-3) were obtained in collaboration with the VIB Nanobody Service Facility as described earlier (11) . In short, dromedaries were injected with either cytoplasmic gelsolin or biotinylated human gelsolin 8 kDa AGel peptide and recombinant GST-tagged human D187N gelsolin domain 2. Lymphocytes were collected from the blood, total RNA was extracted and a cDNA library constructed. Phage panning for the anti-gelsolin nanobodies was performed with cytoplasmic gelsolin and resulted in two functional nanobodies; Nb11 and Nb13 (32) . Phage panning for the anti-gelsolin nanobodies was performed with the 8 kDa peptide and the mutant G2 domain. Three nanobodies could be identified; FAF Nb1-3.
cDNA cloning
All monovalent nanobodies were available in the pHEN6 vector with a C-terminal V5-His 6 tag. The bispecific nanobodies were constructed as follows: the pHEN6 vector containing the FAF Nb1-3-V5-His 6 constructs was cleaved with NcoI, opening the vector between the pelB signal and nanobody N-terminus. The Nb11 sequence was amplified with a double set of primers to introduce a 5' HA-tag and a 3' linker sequence (Fig. 1A) . This sequence encodes a MT1-MMP sensitive peptide (SLAPLGLQRR) flanked by two GS linkers. The Cold Fusion Kit (System Biosciences, Mountain View, CA) was used to ligate the PCR fragment in the opened pHEN6 vector.
Primers used in the first PCR cycle: 5' GGT GGT GGT GGT TCT GGT CAG GTG CAG CTG CAG GAG TCT GG 3' (forward) and 5' GAC GCT GCA GAC CCA GCG GCG CCA GAG AAC CAG AAC CAC CAC CAC CGC TGG AGA CGG TGA CCT GGG TCC C 3' (reverse).
Primers used in the second PCR cycle, using the product of the first cycle as template: 5' CGC GGC CCA GCC GGC CAT GGC CTA CCC ATA CGA TGT TCC AGA TTA CGC TGG TGG TGG TGG TTC TGG TCA GGT G 3' (forward) and 5' CCT CCT CCA GAC TCC TGC AGC TGC ACC TGA CCA GAA CCA CCA CCA CCA CGA CGC TGC AGA CCC AGC GGC GCC AG 3' (reverse).
Purification of recombinant PG*, C68 and nanobodies
Performed as previously described (11) .
ELISA
Enzyme-linked immunosorbent assays (ELISA) were performed in Nunc Maxisorp 96-well plates (Roskilde, Denmark). Target protein was coated in coating buffer (100 mM bicarbonate/carbonate, pH 9.6) at 0.2 mg of protein per well. PBS þ 1% BSA was used as a blocking buffer, PBS þ 0.5% Tween was used as a washing buffer. Nanobodies were added in a ten-fold dilution series ranging from 1 mg to 10 À 5 mg/well. Anti-V5 antibody followed by anti-mouse HRP þTMB substrate kit (3,3',5,5' tetramethylbenzidine, Thermo Scientific, Erembodegem, Belgium) was used for detection.
WB with bispecific Nb11-FAF nanobodies as primary antibody
Bacterial pellets containing PG, PG*, C68, 8 kDa peptide or CapG were resuspended in lysisbuffer þ 0.5% NP40. Lysis was performed with 0.2 mg/ml lysozyme for 30 min at room temperature followed by sonication (Vibracell, Sonics and Materials, Newtown, CT). The lysates were collected after 30 min of centrifugation at 29.000 x g, 4 C. 5 mg bacterial protein extract were fractionated by SDS-PAGE. Western blot analysis was performed with V5-tagged Nb11-FAF1, 2 and 3 as primary antibody. Monoclonal anti-gelsolin antibody was used as a positive control.
In vitro MT1-MMP sensitive linker assay
In vitro MT1-MMP proteolysis of the Nb11-FAF constructs was performed in a total reaction volume of 75 ml. 2.5 mg bispecific Nb11-FAF Nb1-3 was incubated with 100 ng of the catalytic domain of MT1-MMP for 1 h at 37 C in reaction buffer (50 mM Tris pH 7.5, 5 mM CaCl 2 , 200 mM NaCl, 20 mM ZnSO 4 and 0.05% Brij-35). At 0, 15, 30, 45 and 60 min, samples were taken and the reaction was terminated by adding 5 ml Laemmli sample buffer. Samples were boiled for 5 min, fractionated on a 15% SDS-PAGE gel and stained with Coomassie.
In vitro furin/MT1-MMP assay
The in vitro proteolytic furin and MT1-MMP reaction was performed in a total end volume of 20 ml. 
HEK293T cell culture, transfection and microscopy
Cell culture and transfection. HEK293T cells were grown in DMEM medium (Gibco Life Technologies, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (Thermo Scientific, Erembodegem, Belgium), 10 mg/ml streptomycin and 10 IU/ml of penicillin, at 37 C in a humidified 10% CO 2 incubator. Transient expression of both PG and the nanobodies was achieved with Jetprime (Polyplus Transfection Inc., New York, NY). Microscopy. Cells were fixed with 3% PFA (paraformaldehyde) and permeabilized with 0.1% Triton. Coverslips were blocked with 1% BSA (bovine serum albumin) and incubated with primary antibodies (1 h at 37 C). The appropriate Alexa Fluor- 
HEK293T medium analysis
HEK293T cells were cultured and transiently transfected as described above. 24 h prior to analysis the cell medium was replaced with a minimum amount of serum free medium. The medium was collected and centrifuged (29.000 x g) for 5 min at 4 C. The cells were washed 2 times with PBS and disrupted in
Tris lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% triton-100, 1 mM PMSF and 200 mg/ml protease inhibitor cocktail) followed by 10 s of sonication. Samples were centrifuged (29.000 x g) for 10 min at 4 C, the supernatant was collected. 20 mg of the medium was separated on a 10% SDS-PAGE gel followed by Western blot analysis.
AAV9 gene therapy intervention study
The gene encoding the V5-tagged bispecific Nb11-FAF1 nanobody was cloned downstream of a ubiquitously expressed cytomegalovirus (CMV) promoter. This expression cassette was cloned into a self-complementary (sc) AAV backbone (33) to generate the AAV9-Nb11-FAF1 vector (Fig. 1B) . As before AAV9-Luc2 vector was chosen as viral control (19) . AAV serotype 9 (AAV9) was chosen based on its efficient transduction efficiency in skeletal muscle and heart (19, 21, 23) . To produce the AAV9-Nb11-FAF1 vector particles, AAV-293 cells were co-transfected by calcium phosphate (Invitrogen Corp, Carlsbad, CA, USA) with the AAV9-Nb11-FAF1 vector along with a chimeric AAV Rep2 Cap9 packaging construct and an adenoviral helper plasmid, as described previously [39] . All plasmids were prepared using Qiagen Maxi kits. Two days after transfection, the cells were harvested and lysed by freeze/thaw cycles and sonication, followed by benzonase (Novagen, Madison, WI, USA) and deoxycholic acid (Sigma-Aldrich, St Louis, MO, USA) treatments. The cognate AAV vector particles were then purified by cesium chloride (Invitrogen Corp, Carlsbad, CA, USA) density gradient ultracentrifugation. Fractions containing the AAV vector particles were collected in phosphate buffered saline (PBS) (Gibco, BRL) containing 1 mM MgCl 2 . The vector titer was determined using quantitative real-time PCR with SYBRV R Green and primers specific for the CMV promoter. The forward primer sequence was 5' CAT GGT GAT GCG GTT TTG G 3'. The reverse primer sequence was 5' TGG AAA TCC CCG TGA GTC A 3'. To generate standard curves, known copy numbers of the corresponding vector plasmid was used. The intervention study was performed on 2 groups of mice: WT C57BL/6 and AGel mice. Each group consisted of 3 subgroups (6-12 mice): AAV9-Nb11-FAF1 injected (treatment), AAV9-Luc2 injected (viral control) and PBS injected (negative control). Neonatal mice (2-3 days) were injected with 4.7x10 
SPECT-CT imaging
Amyloid burden was visualized using 99m
Tc-FAF Nb1 SPECT-CT imaging (14) . Mice were intravenously injected with 51-100 MBq of 99m Tc labeled FAF Nb1. One hour post injection, mice were anaesthetized using 18.75 mg/kg ketamine hydrochloride (Ketamine 1000, CEVA) and 10 mg/kg xylazine hydrochloride (Rompun, Bayer). Animals were positioned in a solid holder with two plastic discs containing three 57 Co (3.7 MBq) sources. Image acquisition was done using a micro-CT scan for 2 min (60 keV, 615 mA, 360
; Skyscan 1178, Kontich, Belgium) and a dual-headed SPECT camera (e.cam 180, Siemens, USA) equipped with triple pinhole collimators (1.5 mm apertures, focal length of 265.5 mm and a radius of rotation of 20 mm) for 10 s per projection step, 64 projections, and a total scan time of about 10 min. Images were quantified using AMIDE (a Medical Image Data Examiner) software (34) . Ellipsoid regions of interest were drawn (ROIs) around the heart and hind leg muscle. The same ROI heart and ROI muscle was used for each individual animal. SPECT signals, acquired from the ROIs, were calculated and expressed as % IA/cc.
Muscle contractile properties
Muscle contractile properties were determined as described before (35) . In short, mice were anaesthetized with 80% Ketalar/ 20% Rompun (3.6 ml/g body weight). The soleus and EDL muscles were dissected, wires were attached to the tendons and the muscles were vertically mounted in an Krebs-Heinseleit medium incubation bath with one tendon attached to a force transducer (PowerLab, ADInstruments, Spechback, Germany) and stimulated with capacitor discharges between platinum electrodes. The Krebs-Henseleit incubation medium (10 ml) was continuously gassed (95% O 2, 5% CO 2 ) and maintained at 30 C.
After a 15 min stabilization period, optimal muscle length was determined by titanic contractions. Next, the force-frequency relation was determined by stimulating at 10, 20, 35, 50, 75, 100, and 125 Hz with 1 min rest interval for soleus and stimulating at 25, 40 and 55 with 1 min rest followed by 70, 100, 125 and 150 Hz with 2 min rest interval, unless stated otherwise, for EDL. Furthermore, fatigability was evaluated as the percentage decrease in tetanic force, contraction speed (maximum slope) and relaxation rate (minimum slope) values during 8 min of repeated tetanic contractions (train duration, 350 microseconds; soleus, 50 Hz every 5 s; EDL, 100 Hz every 10 s). At the end, mice were euthanized via cervical dislocation.
Immunofluorescence
Musculus gastrocnemius and the heart were dissected and snap frozen in liquid nitrogen. Cryosections were made and thawed for 15 min followed by 10 min incubation in acetone at -20 C.
After 10 min incubation in PBS, the sections were incubated in 50 mM NH 4 Cl/PBS for another 10 min followed by an additional PBS washing step. The endogenous peroxidase activity was blocked after 20 min incubation in 0.3% H 2 O 2 and then washed in PBS. Sections were incubated with 1% BSA/PBS for 20 min and with the laminin antibody (1:500) at 4 C overnight, followed by another PBS washing step for 10 min. FAF Nb1-V5 (5 lg/ml) was incubated for 1 h at room temperature followed by 10 min incubation in PBS. Polyclonal anti-V5 (1:800) was used as secondary antibody. Alexa Fluor antibodies (488 anti-rat and 594 antirabbit, both 1:500) were incubated for 1 h at room temperature. Finally, sections were rinsed with PBS, stained with DAPI (1:500) for 2 min and mounted with VectaShield. Imaging was performed at room temperature with a Leica DM6000 B microscope. Two sections were made per tissue and within each section, 3 images from spate regions were taken for quantification with Image J software. From these 6 technical repeats per animal, per tissue, the average was used for further statistical calculations.
Supplementary Material
Supplementary Material is available at HMG online.
